Tectonic Therapeutic, Inc. TECX
18.98 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:01 PM EST
18.98 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
18.76 Day range 19.74
15.52 52-week range 39.53
- YTD
- -9.01%
- 1 year
- +8.40%
- Market cap
- 371.05M
- EPS (ttm)
- -4.57
- Shares out
- 14.75M
- Forward P/E
- -10.16
- YTD return
- -9.01%
- 1-year return
- +8.40%
- Volume
- 198.95K
- Avg volume
- 220.29K
- Open
- 19.13
- Previous close
- 18.98
- Day's range
- 18.76 – 19.74
- 52-week range
- 15.52 – 39.53
- Analysts
- Strong Buy
- Price target
- 74.67 (+293.4%)
- Earnings date
- Aug 14, 2024
2Y -22.88 (-54.65%)
Key statistics
- Enterprise value
- 517.32M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 185.12M
- Total debt
- 3.44M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 43.40
- 200-day average
- 24.05
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 74.67 +293.4% upside
Now 18.98
- Target (low)
- 69.00
- Target (mean)
- 74.67
- Target (high)
- 79.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
TECX Revenue — quarterly 0
TECX Net income — quarterly -22.29M
TECX EPS — quarterly -1.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.84 | -1.20 | -0.36 | -42.86% |
| Aug 14, 2024 | Jun 1, 2024 | -1.96 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -1.96 | -3.81 | -1.85 | -94.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Raymond James | init | — | Outperform |
| Nov 12, 2024 | Wells Fargo | main | Overweight | Overweight |
| Nov 11, 2024 | Leerink Partners | main | Outperform | Outperform |
| Aug 22, 2024 | Wells Fargo | init | — | Overweight |
| Jul 24, 2024 | Leerink Partners | init | — | Outperform |
| Jun 26, 2024 | Piper Sandler | init | — | Overweight |
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tectonictx.com
News
Tectonic Therapeutic, Inc. (TECX) – What Are Researchers Thinking About This Stock? 
UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26 
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) 
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Stock Has Average Price Target of $77.25 According to Analysts 
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference 
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case 
Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93 
Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate 
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights 
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Your note
Sign in to keep a note on TECX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CORTIS CHRISTIAN | Chief Operating Officer | Stock Award(Grant) | Jun 19, 2024 | 126,368 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 13, 2024 | 0 |
| MCGUIRE TERRANCE G | Director | Stock Award(Grant) | Jun 19, 2024 | 0 |
| MCNAMARA PETER | Officer | Conversion of Exercise of derivative security | Dec 2, 2024 | 14,188 |
| REICIN ALISE S | Chief Executive Officer | Stock Award(Grant) | Dec 3, 2024 | 302,827 |
| RUDDY MARCELLA KUHLMAN M.D. | Officer | Stock Award(Grant) | Jun 19, 2024 | 32,065 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 8.27% | 1,220,138 | 58.03M | Sep 29, 2024 |
| Vida Ventures Advisors, LLC | 6.97% | 1,028,674 | 48.92M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 5.76% | 849,143 | 40.39M | Sep 29, 2024 |
| 5AM Venture Management, LLC | 4.38% | 646,524 | 30.75M | Sep 29, 2024 |
| Farallon Capital Management LLC | 3.53% | 520,397 | 24.75M | Sep 29, 2024 |
| Vanguard Group Inc | 3.00% | 442,814 | 21.06M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.59% | 381,589 | 18.15M | Sep 29, 2024 |
| Fidelity Advisor Biotechnology Fund | 0.97% | 142,600 | 6.78M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.30% | 44,790 | 2.13M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.26% | 38,226 | 1.82M | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.13% | 18,948 | 901.17K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.13% | 18,564 | 882.90K | Oct 30, 2024 |